A Dynamic DNA Nano‐Antioxidant Targeting Galectin‐3 Attenuates Liver Fibrosis via Reducing Macrophage Oxidative Stress
Authors:
Open Access
- 30 October 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (4) , e09977
Abstract
Liver cirrhosis represents a major global health challenge with significant socioeconomic implications. Oxidative stress‐mediated injury plays a pivotal role in driving fibrotic progression, with hepatic macrophages serving as a dominant source of reactive oxygen species (ROS). Consequently, targeted suppression of macrophage‐derived ROS presents a promising therapeutic strategy. Single‐cell RNA sequencing analysis identified Galectin‐3 as positively correlated with macrophage oxidative stress and ROS production. Here, a dynamic DNA nano‐antioxidant (DDN) is developed for hepatic macrophage‐specific small interfering RNA (siRNA) delivery targeting Galectin‐3. DDN administration achieved a 3.92‐fold reduction in Galectin‐3 expression, with transcriptomic profiling revealing restoration of Nuclear Factor Erythroid 2‐Related Factor 2 (NRF2) signaling and consequent attenuation of oxidative stress in macrophages. Pharmacokinetic assessment via IVIS imaging demonstrated superior hepatic accumulation of DDN, exhibiting 1.57‐ and 2.11‐fold greater fluorescence intensity at 240 min post‐injection compared to siRNA and tetrahedral framework nucleic acid (tFNA), respectively. In a carbon tetrachloride (CCl 4 )‐induced mouse model, intraperitoneal DDN administration significantly reduced macrophage oxidative burden, ROS generation, and M1 polarization, ultimately mitigating collagen deposition and fibrotic progression. These findings establish DDN as a potent and targeted therapeutic platform for liver fibrosis treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82501041)
This publication has 46 references indexed in Scilit:
- Kidney-targeting DNA tetrahedral molecular cage synergistically inhibits acute kidney injury by clearing ROS and activating HO-1Biomaterials, 2025
- Advances in DNA nanotechnology for chronic wound management: Innovative functional nucleic acid nanostructures for overcoming key challengesJournal of Controlled Release, 2024
- RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapyClinical and Translational Medicine, 2024
- A Novel Bioswitchable miRNA Mimic Delivery System: Therapeutic Strategies Upgraded from Tetrahedral Framework Nucleic Acid System for Fibrotic Disease Treatment and Pyroptosis Pathway InhibitionAdvanced Science, 2023
- RNA‐Cleaving DNAzyme‐Based Amplification Strategies for Biosensing and TherapyAdvanced Healthcare Materials, 2023
- Liver macrophages in health and diseaseImmunity, 2022
- A Tetrahedral Framework DNA‐Based Bioswitchable miRNA Inhibitor Delivery System: Application to Skin Anti‐AgingAdvanced Materials, 2022
- Functionalizing Framework Nucleic‐Acid‐Based Nanostructures for Biomedical ApplicationAdvanced Materials, 2021
- Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS OutputCell, 2020
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995